

**Supplementary Table 3.** Odds ratios for the hepatic fibrosis stages according to u-NCR in insulin non-user ( $n=249$ )

Model	Hepatic fibrosis stage 2 (F2)		Hepatic fibrosis stage 3 (F3+4)	
	aOR (95% CI)	<i>P</i> value	aOR (95% CI)	<i>P</i> value
1	2.39 (1.34–4.26)	0.003 <sup>a</sup>	2.55 (1.47–4.42)	0.001 <sup>a</sup>
2	2.27 (1.28–4.04)	0.005 <sup>a</sup>	2.19 (1.33–3.63)	0.002 <sup>a</sup>
3	2.07 (1.12–3.82)	0.020 <sup>a</sup>	2.17 (1.35–3.47)	0.001 <sup>a</sup>
4	1.99 (1.04–3.82)	0.039 <sup>a</sup>	2.40 (1.52–3.80)	<0.001 <sup>a</sup>

Model 1 was adjusted for age, male sex, body mass index, and duration of diabetes; Model 2 adjusted for Model 1 parameters plus hypertension, lipid medication; Model 3 adjusted for Model 2 parameters plus triglyceride, alanine aminotransferase, homeostasis model assessment of insulin resistance; Model 4 adjusted for Model 3 parameters plus glycosylated hemoglobin, homeostasis model assessment- $\beta$ .  
u-NCR, urinary *N*-acetyl- $\beta$ -D-glucosaminidase to creatinine ratio; aOR, adjusted odds ratio; CI, confidence interval.

<sup>a</sup>Statistical significance at  $P < 0.05$ .